nach oben

Annals of Hematology

Erschienen in:

01.12.2005 | Original Article

Decitabine: a historical review of the development of an epigenetic drug

verfasst von: Dick de Vos, Wendy van Overveld

Erschienen in: Annals of Hematology | Sonderheft 1/2005

Einloggen, um Zugang zu erhalten

Abstract

The development of decitabine from its synthesis in 1964 to the submission of a registration file has been described. Although the unique DNA-demethylating capacity of decitabine is known for a long time, its application is under continuing investigation. The use of decitabine in MDS, AML, CML, stem cell transplant, sickle cell anemia and thalassemia looks promising. The epigenetic dose seems lower than the cytotoxic dose. Whereas most drugs have matured after 40 years, decitabine is only at the beginning of a new development phase in epigenesis.

Abbruzzese J, Raber M, Vrijhof W et al (1991) A phase I trial of laboratory derived synergistic chemotherapeutic (sc) combination: 2′ deoxy-5-azacytidine (DAC) and cisplatin (CDDP). Proc Am Assoc Cancer Res 32:204 (abstr 1219)

Abele R, Clavel M, Dodion P, Bruntsch U, Gundersen S, Smyth J, Renard J, van Glabbeke M, Pinedo HM (1987) The EORTC early clinical trials group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colorectal, head and neck, renal carcinomas and malignant melanomas. Eur J Cancer 23:1921–1924

Aparicio A, Eads CA, Leong LA et al (2003) Phase I trial of continuous infusion 5-aza-2′-deoxycytidine. Cancer Chemother Pharmacol 51:231–239PubMed

Bosch van den J, Lübbert M, Verhoef G (2004) The effects of 5-aza-2′-deoxycytidine (decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk Res 28:785–790CrossRef

Bouchard J, Momparler RL (1983) Incorporation of 5-aza-2′-deoxycytidine 5′-triphosphate into DNA. Interactions with mammalian DNA polymerase and DNA methylase. Mol Pharmacol 24:109–114PubMed

Chabot G, Bouchard J, Momparler RL (1983) Kinetics of deamination of 5-aza-2′-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine, and uracil arabinoside. Biochem Pharmacol 32:1327–1328PubMedCrossRef

Constantinides PG, Taylor SM, Jones PA (1978) Phenotypic conversion of cultured mouse embryo cells by aza pyrimidine nucleosides. Dev Biol 66:57–71PubMedCrossRef

Davies MJ, Jenkins PR, Prouse LSJ et al (1991) Structure of 2′-deoxy-5-azacytidine (decitabine) monohydrate. Acta Crystllogr C47:1418–1420CrossRef

Egger G, Liang G, Aparicio A et al (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429:457–463PubMedCrossRef

10.

Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM (2004) Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoetic malignancies. Blood 103:1635–1640PubMedCrossRef

11.

Jones PA, Taylor SM (1980) Cellular differentiation, cytidine analogs and DNA methylation. Cell 20:85–93PubMedCrossRef

12.

Jones PA, Taylor SM, Mohandas T et al (1982) Cell cycle-specific reactivation of an inactive X-chromosome locus by 5-azadeoxycytidine. Proc Natl Acad Sci U S A 79:1215–1219PubMedCrossRef

13.

Kantarjian HM, O'Brien SM, Keating M, Beran M, Estey E, Giralt S, Kornblau S, Rios MB, de Vos D, Talpaz M (1997) Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukaemia. Leukemia 11:1617–1620PubMedCrossRef

14.

Kantarjian HM, Pinto A (eds) (1997) Workshop on the clinical results with decitabine (5-aza-2′-deoxycytabine) in hematologic malignancies. Leukemia 11(suppl monograph 1)

15.

Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Faderl S, Issa JP, Garcia-Manero G, Rios MB, Shan J, Andreeff M, Keating M, Talpaz M (2003) Results of decitabine (5-aza-2′-deoxycytidine) therapy in 130 patients with chronic myeloid leukaemia. Cancer 98:522–528PubMedCrossRef

16.

Koshy M, Dom L, Bressler L, Molokie R, Lavelle D, Talischy N, Hoffman R, van Overveld W, DeSimone J (2000) 2′-deoxy-5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood 96:2379–2384PubMed

17.

Lima de M, Ravandi F, Shahjahan M, Andersson B, Couriel D, Donato M, Khouri I, Gajewski J, van Besien K, Champlin R, Giralt S, Kantarjian H (2003) Long-term follow-up of a phase I study of high dose decitabine, busulfan, and cyclophosphamide plus allogenic transplantation for the treatment of patients with leukemias. Cancer 97:1242–1247CrossRef

18.

Lübbert M, Wijermans P, Kunzmann R, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A (2001) Cytogenetic responses in high-risk myelodysplastic syndrome following low dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br J Haematol 114:349–357PubMedCrossRef

19.

Lübbert M, Daskalakis M, Kunzmann R, Engelhardt M, Guo Y, Wijermans P (2004) Nonclonal neutrophil responses after successful treatment of myalodysplasia with low dose 5-aza-2′-deoxycytidine (decitabine). Leuk Res 28:1267–1271PubMedCrossRef

20.

Meulenbelt-Snijders SJ, Meulenbelt F, Paalman ACA et al (1984) Formulering van 5-aza-2′-deoxycytidine, een experimenteel cytostaticum. Pharm Weekbl 119:1186–1189

21.

Momparler RL (1979) Pharmacology of 5-aza-2′-deoxycytidine. FEBS Symp 1979, Antimetab Biochem Biol Med 57:33–41

22.

Momparler RL, Bouchard J, Onetto N, Rivard GE (1984) 5-Aza-2′-deoxycytidine therapy in patients with acute leukaemia inhibits DNA methylation. Leuk Res 8:181–185PubMedCrossRef

23.

Momparler RL, Rossi M, Bouchard J, Vacaro C, Momparler LF (1984) Kinetic interaction of 5-aza-2-deoxycytidine 5′-monophosphate and its 5′-triphosphate with deoxycytilate deaminase. Mol Pharmacol 25:436–438PubMed

24.

Momparler RL, Rivard GE, Gyger M (1985) Clinical trial on 5-aza-2′-deoxycytidine in patients with acute leukaemia. Pharmacol Ther 30:277–286PubMedCrossRef

25.

Momparler RL, Vos de D (eds) (1990) 5-Aza-2′-deoxycytidine. Preclinical and clinical studies. PCH Publications, Haarlem, The Netherlands

26.

Momparler RL, Bouffard DY, Momparler LF et al (1997) Pilot phase I–II study on 5-aza-2′-deoxycytidine (decitabine) in patients with metastaic lung cancer. Anticancer Drugs 8:358–368PubMedCrossRef

27.

Momparler RL, Eliopoulos N, Ayoub J (2000) Evaluation of an inhibitor of DNA methylation, 5-aza-2′-deoxycytidine for the treatment of lung cancer and the future role of gene therapy. Adv Exp Med Biol 465:433–446PubMedCrossRef

28.

Momparler RL, Ayoub J (2001) Potential of 5-aza-2′-deoxycytidine (decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer. Lung Cancer 34(Suppl 4):S111–S115PubMedCrossRef

29.

Pliml J, Sorm F (1964) Synthesis of 2′-deoxy-d-ribofuranosyl-5-azacytosine. Coll Czech Chem Commun 29:2576–2577

30.

Pinto A, Attadia V, Di Fiore PP et al (1983) 2′-Deoxy-5-azacytidine induces functional and morphological differentiation of a human erythroleukemic cell line (K562). In: Rich MA (ed) Leukemia review international 1. Marcel Dekker, New York, pp 207–208

31.

Pinto A, Attadia V, Fusco A, Ferrara F, Spada OA, Di Fiore PP (1984) 5-Aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood 64:922–929PubMed

32.

Pinto A, Maio M, Attadia V, Zappacosta S, Cimino R (1984) Modulation of HLA-DR antigens expression in human myeloid leukaemic cells by cytarabine and 5-aza-2′-deoxycytidine. Lancet 2:867–868PubMedCrossRef

33.

Pinto A, Attadia V (1986) Leukemia therapy by differentiation inducers: the therapeutic concept of differentiation. Cancer J 1:54

34.

Pinto A (eds) (1993) 5-Aza-2′-deoxycytidine and DNA methyltransferase inhibitors in thehttp://www.nytimes.com/2005/03/16/nyregion/16ferrer.html treatment of myeloid leukemias and myelodysplastic syndromes: biological aspects and clinical results. Leukemia 7(suppl 1)

35.

Piskala A, Sorm F (1978) Anomeric 4-amino-1-(2-deoxy-d-erythro-pentofuranosyl)-s-triazin-2(1H)-ones (2′-deoxy-5-azacytidine and its α-d anomer). Synthesis of 5-azapyrimidine deoxyribonucleosides via acylglucosyl isocyanates. Nucleic Acid Chem 1:443–449

36.

Piskala A, Synackova M, Tomankova H et al (1978) Direct synthesis of 5-azapyrimidine 2′-deoxyribonucleosides. Hydrolysis of 5-aza-2′-deoxycytidine. Nucleic Acid Res Spec Publ 4:109–113

37.

Pohlmann P, DiLeone LP, Cancella AI et al (2002) Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous carcinoma of the cervix. Am J Clin Oncol 25:496–501PubMedCrossRef

38.

Ravandi F, Kantarjian H, Cohen A, Davis M, O'Brien S, Anderlini P, Andersson B, Claxton D, Donato M, Gajewski J, Khouri I, Korbling M, Ueno N, deVos D, Champlin R, Giralt S (2001) Decitabine with allogenic peripheral blood stem cell transplantation in the therapy of leukaemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant 27:1221–1225PubMedCrossRef

39.

Richel DJ (1990) Experimental therapy in Ara-C sensitive and resistant leukaemia, Ph.D. thesis. University of Leiden. The Netherlands

40.

Richel DJ, Colly LP, Kluin-Nelemans JC, Willemze R (1991) The antileukaemic activity of 5-aza-2′-deoxycytidine (Aza-dC) in patients with relapsed acute leukaemia. Br J Cancer 64:144–148PubMed

41.

Rivard GE, Momparler RL, Demers J et al (1981) Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia. Leuk Res 5:453–462PubMedCrossRef

42.

Ruter B, Wijermans PW, Lübbert M (2004) DNA methylation as a therapeutic target in hematologic disorders: recent results in older patients with myodysplasia and acute myeloid leukaemia. Int J Hematol 80:128–135PubMedCrossRef

43.

Sachs L (1978) The differentiation of myeloid leukaemia cells: new possibilities for therapy. Br J Haematol 40:509–517PubMedCrossRef

44.

Schwartsmann G, Schunemann H, Gorini CN et al (2000) A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. Invest New Drugs 18:83–91PubMedCrossRef

45.

Sessa C, Ten Bokkel Huinink W, Stoter G, Renard J, Cavalli F (1990) Phase II study of 5-aza-2′-deoxycytidine in advanced ovarian cancer. Eur J Cancer 26:137–138PubMedCrossRef

46.

Sorm F, Vesely J (1968) Effect of 5-aza-2′-deoxycytidine against leukemic and hemopoietic tissues in AKR mice. Neoplasma 15:339–343PubMed

47.

Thibault A, Figg WD, Bergan RC et al (1998) A phase II study of 5-aza-2′-deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori 84:87–89PubMed

48.

van Groeningen CJ, Leyva A, O'Brien AM, Gall HE, Pinedo HM (1986) Phase I and pharmacokinetic study of 5-aza-2′-deoxycytidine (NSC 127716) in cancer patients. Cancer Res 46:4831–4836PubMed

49.

Vermorken JB, Tumolo S, Roozendaal KJ, Guastalla JP, Splinter TA, Renard J (1991) 5-Aza-2′-deoxycytidine in advanced or recurrent cancer of the cervix. Eur J Cancer 27:216–217PubMed

50.

Wijermans P, Lübbert M, Verhoef G et al (2000) Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 18:956–962PubMed

51.

Willemze R, Stegman APA, Colly LP (1990) The use of 5-aza-2′-deoxycytidine (DAC) in adult patients with acute leukaemia (abstr). Haematologica 76:43

Titel: Decitabine: a historical review of the development of an epigenetic drug
verfasst von: Dick de Vos
Wendy van Overveld
Publikationsdatum: 01.12.2005
Verlag: Springer-Verlag
Erschienen in: Annals of Hematology / Ausgabe Sonderheft 1/2005
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-005-0008-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2005

An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients

Clinical experience with decitabine in North American patients with myelodysplastic syndrome

Epigenetic therapy in MDS and acute AML: focus on decitabine

Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts

Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine